Bimatoprost Ophtalmic Solution

LATISSE 0.03%, approved by the U.S. Food and Drug Administration (FDA) in 2008, is a novel treatment for hypotrichosis of the eyelashes. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. LATISSE is the first and only FDA-approved, science-based treatment to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes.

Prescription Product Call to Order Prescription Product Call to Order*Prescription Product Call to Order*

The only FDA-approved prescription treatment for hypotrichosis

Contains: 5 ml (0.16 fl oz)